Trial site
Multiprofile Hospital For Active Treatment Pazardzik AD
Pazardzhik, 4400, BulgariaEU-13 widening countryNot linked to an institution yet
- 9running trials
- 3closed trials
The trials here
What the 12 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 23 trials
- Status
- Active, not recruiting5 trials
- Completed3 trials
- Recruiting3 trials
- Not yet recruiting1 trial
- Lead sponsor
- Cardurion Pharmaceuticals Inc.2 trials
- Anthos Therapeutics, Inc.1 trial
- Bayer1 trial
- Celldex Therapeutics1 trial
- Ionis Pharmaceuticals, Inc.1 trial
- and 6 more
Running trials
Not yet recruiting
A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
NCT07931599· Phase 3· Novo Nordisk A/S· Source
Recruiting
Study to assess the safety, tolerability, and effects of vortosiran in two groups: participants who previously had a blood clot and completed initial blood-thinner treatment, and participants with cancer who are at high risk of blood clots
2026-525479-15-00· Phase 2· Ribocure Pharmaceuticals AB· Source
Not yet recruiting
A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF)
(CALIBRATE-HF)
2025-525033-31-00· Phase 2· Cardurion Pharmaceuticals Inc.· Source
Recruiting
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
2023-504358-36-00· Phase 3· Sanofi-Aventis Recherche & Developpement· Source
Active, not recruiting
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202· Phase 3· Celldex Therapeutics· Source
Active, not recruiting
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486· Phase 3· Sanofi· Source
Active, not recruiting
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183· Phase 3· Pfizer· Source
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200· Phase 3· Anthos Therapeutics, Inc.· Source
Active, not recruiting
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
NCT05681351· Phase 3· Ionis Pharmaceuticals, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error